Evidence map›Paper›PMID 27768743›Full record

ArticlePloS one2016

Evaporimeter and Bubble-Imaging Measures of Sweat Gland Secretion Rates.

Jeeyeon Kim, Miesha Farahmand, Colleen Dunn, Zoe Davies, Eric Frisbee, Carlos Milla, Jeffrey J Wine

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04026568 phase2 / phase3terminatednot on this mapstarted 2021, after this paper: background citation

A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma

TypeinterventionalSponsorMilton S. Hershey Medical CenterRan2021 to 2022Enrolled1ConditionsNerve InjuryArms4-Aminopyridine, Placebo oral tablet
NCT06003166 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Pharmaco-Diagnostic Crossover Trial for Peripheral Nerve Continuity After Trauma

TypeinterventionalSponsorUniversity of ArizonaRan2025 to 2028Enrolled68ConditionsPeripheral Nerve Injury, Crush InjuryArms4-Aminopyridine, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Assays of CFTR Function In Vitro, Ex Vivo and In Vivo.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jeeyeon KimCystic Fibrosis Research Laboratory, Stanford University, Stanford, California, United States of America.
Miesha FarahmandCystic Fibrosis Research Laboratory, Stanford University, Stanford, California, United States of America.
Colleen DunnDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.
Zoe DaviesDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.
Eric FrisbeeCystic Fibrosis Research Laboratory, Stanford University, Stanford, California, United States of America.
Carlos MillaDepartment of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.
Jeffrey J WineCystic Fibrosis Research Laboratory, Stanford University, Stanford, California, United States of America.
Stanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Beta-adrenergically-stimulated sweat rates determined by evaporimetry or by sweat bubble imaging are useful for measuring CFTR function because they provide a near-linear readout across almost the full range of CFTR function. They differentiate cystic fibrosis (CF) subjects from CF carriers and carriers from controls. However, evaporimetry, unlike bubble imaging, appears to be unable to detect improved levels of CFTR function in G551D subjects taking the CFTR modulator ivacaftor. Here, we quantify the sensitivity of evaporimetry and bubble imaging methods for assessing low levels of CFTR-dependent sweat rates. To establish sensitivity, we did dose-ranging studies using intradermally injected [cAMP]i-elevating cocktails. We reduced isoproterenol/aminophylline levels while maintaining a high level of atropine to block muscarinic elevation of [Ca2+]i. We stimulated the same sets of glands for both assays and recorded responses for 20 min. In response to a 3-log dilution of the stimulating cocktail (0.1%), bubble responses were detected in 12/12 tests (100%), with 49% ± 3% of glands secreting to produce an aggregate volume of 598 nl across the 12, 20-min tests. This was ~5% of the response to full cocktail. Evaporimetry detected responses in 3/12 (25%) tests with an aggregate secretion volume of 175 nl. After stimulation with a still more dilute cocktail (0.03%), bubble imaging detected 15 ± 13% of glands secreting at a rate ~0.9% of the response to full cocktail, while zero responding was seen with evaporimetry. The bubble imaging method detected secretion down to aggregate rates of <0.2 nl/(cm2·min), or ~1/30th of the average basal transepithelial water loss (TEWL) in the test subject of 4 g/m2·hr or 6.7 nl/(cm2·min). The increased sensitivity of bubble imaging may be required to detect small but physiologically important increases in secretion rates produced by CFTR modulators.

Indexed as

AdultAminophyllineCyclic AMPCystic Fibrosis Transmembrane Conductance RegulatorFemaleHumansIsoproterenolMaleSweat GlandsAminophyllineCFTR protein, humanCyclic AMPCystic Fibrosis Transmembrane Conductance RegulatorIsoproterenol

Identifiers

PMID27768743
PMCPMC5074501
OpenAlexW2533377295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.